Stock RLMD RELMADA THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Relmada Therapeutics, Inc.

Equities

RLMD

US75955J4022

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-23 pm EDT 		5-day change 1st Jan Change
3.91 USD +1.03% Intraday chart for Relmada Therapeutics, Inc. -14.25% -5.56%
Mar. 19 Transcript : Relmada Therapeutics, Inc., 2023 Earnings Call, Mar 19, 2024
Mar. 19 Relmada Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Evolution of the average Target Price on Relmada Therapeutics, Inc.

Price target over the last 5 years

History of analyst recommendation changes

1e28a.hOKFMJNTW1ri3_bv659xWrCENFn3FjWlMViDxs_s1f4.sNLUAPsrPjSAkMPd2d4bbvG3Wm6dd2XoBWv1rp-bl8j8rsB59SARYr2tgQ~14ae1c098cc4ddc5a4f1860ef3c57b04

Analyst Recommendations on Relmada Therapeutics, Inc.

SVB Securities Cuts Price Target on Relmada Therapeutics to $10 From $42, Maintains Outperform Rating MT
Oppenheimer Reiterates Relmada Therapeutics Perform Rating, Removes $7 Price Target MT
Goldman Sachs Downgrades Relmada Therapeutics to Neutral From Buy, Adjusts Price Target to $8 From $81 MT
Guggenheim Downgrades Relmada Therapeutics to Neutral From Buy MT
Truist Securities Downgrades Relmada Therapeutics to Hold From Buy, Adjusts Price Target to $10 From $90 MT
Oppenheimer Downgrades Relmada Therapeutics to Perform From Outperform, Adjusts Price Target to $7 From $64 MT
Goldman Sachs Adjusts Price Target on Relmada Therapeutics to $81 From $49, Reiterates Buy Rating MT
Guggenheim Adjusts Price Target on Relmada Therapeutics to $60 From $50, Reiterates Buy Rating MT
Goldman Sachs Adjusts Price Target for Relmada Therapeutics to $49 From $47, Maintains Buy Rating MT
Oppenheimer Adjusts Relmada Therapeutics' Price Target to $64 From $75, Maintains Outperform Rating MT
Goldman Sachs Adjusts Relmada Therapeutics' Price Target to $53 from $69, Keeps Buy Rating MT
SVB Leerink Adjusts Relmada Therapeutics' Price Target to $42 from $50, Keeps Outperform Rating MT
Mizuho Securities Starts Relmada Therapeutics at Buy With $50 Price Target MT
RELMADA THERAPEUTICS : Truist Securities Adjusts Relmada Therapeutics PT to $90 From $75, Maintains Buy Rating MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
5
Last Close Price
3.87 USD
Average target price
10.88 USD
Spread / Average Target
+181.01%
High Price Target
25 USD
Spread / Highest target
+545.99%
Low Price Target
3 USD
Spread / Lowest Target
-22.48%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Relmada Therapeutics, Inc.

SVB Securities LLC
Oppenheimer
Guggenheim
Goldman Sachs
Truist Securities
SVB Leerink
Mizuho Securities

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. RLMD Stock
  4. Consensus Relmada Therapeutics, Inc.